136 related articles for article (PubMed ID: 20421565)
21. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
Winkelmayer WC
J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
[No Abstract] [Full Text] [Related]
22. Erythropoietins should be used according to guidelines.
Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
[No Abstract] [Full Text] [Related]
23. Full results on risks of epoetin emerge 14 years after major dialysis study.
Epstein K
BMJ; 2012 May; 344():e3535. PubMed ID: 22619221
[No Abstract] [Full Text] [Related]
24. Comparative studies on erythropoietic agents.
Straus D
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S46-9. PubMed ID: 16280113
[No Abstract] [Full Text] [Related]
25. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
26. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
[TBL] [Abstract][Full Text] [Related]
27. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
28. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
29. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
[TBL] [Abstract][Full Text] [Related]
30. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
Boccia R; Lillie T; Tomita D; Balducci L
Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
[TBL] [Abstract][Full Text] [Related]
31. New limits advised for anemia drugs.
Mitka M
JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
[No Abstract] [Full Text] [Related]
32. Epoetin alfa and darbepoetin alfa go head to head.
Steensma DP; Loprinzi CL
J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
[No Abstract] [Full Text] [Related]
33. Epoetin versus darbepoetin conundrum compromise.
Bleyer A
J Clin Oncol; 2006 Sep; 24(25):e46. PubMed ID: 16943519
[No Abstract] [Full Text] [Related]
34. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
35. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
Pedrazzoli P; Farris A; Del Prete S; Del Gaizo F; Ferrari D; Bianchessi C; Colucci G; Desogus A; Gamucci T; Pappalardo A; Fornarini G; Pozzi P; Fabi A; Labianca R; Di Costanzo F; Secondino S; Crucitta E; Apolloni F; Del Santo A; Siena S
J Clin Oncol; 2008 Apr; 26(10):1619-25. PubMed ID: 18375891
[TBL] [Abstract][Full Text] [Related]
37. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
38. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
Spaepen E; Demarteau N; Van Belle S; Annemans L
Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
[TBL] [Abstract][Full Text] [Related]
39. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?
Cohen RA; Brown RS
Am J Kidney Dis; 2012 May; 59(5):604-6. PubMed ID: 22361042
[No Abstract] [Full Text] [Related]
40. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
Hollingsworth K; Romney MC; Crawford A; McAna J
Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]